search
Back to results

Safety Study of ISIS 325568 in Healthy Volunteers

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 1
Locations
Netherlands
Study Type
Interventional
Intervention
ISIS 325568
Sponsored by
Ionis Pharmaceuticals, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring diabetes

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Age 18 to 65 years
  2. Males or females. Females must be non-pregnant and non-lactating, and either surgically sterile (hysterectomy, oophorectomy, or tubal ligation) or post-menopausal. Males must be surgically sterile, abstinent or if engaged in sexual relations of child-bearing potential, subject or partner must be using an acceptable contraceptive method during the trial and for 9 weeks after the last dose of study drug.
  3. Give written informed consent to participate in study and availability for all study requirements
  4. Fasting plasma glucose ≤ the upper limit of the laboratory's reference range (ULN)
  5. HbA1C ≤ ULN
  6. BMI < 30 kg/m2

Exclusion Criteria:

  1. Clinically significant abnormalities in medical history or physical examination
  2. Abnormalities on laboratory examination (ALT > ULN, AST > ULN, bilirubin > ULN, creatinine > ULN, urine protein positive by urine dipstick, platelets < lower limit of normal and any other clinically significant laboratory findings)
  3. History of clinically significant abnormalities in coagulation parameters
  4. Positive test result for HIV, hepatitis B virus, and/or hepatitis C virus
  5. Active infection requiring antiviral or antimicrobial therapy
  6. Subjects on chronic or acute prescription medication may be permitted after discussion with the Isis Medical Monitor.
  7. Malignancy (with the exception of basal or squamous cell carcinoma of the skin if adequately treated and no recurrence for > 1 year)
  8. Any other concurrent condition which, in the opinion of the Investigator, would preclude participation in this study or interfere with compliance
  9. History of alcohol or drug abuse
  10. Undergoing or have undergone treatment with another investigational drug, biologic agent or device within 90 days prior to Screening.
  11. Blood donation within three months of screening

Sites / Locations

  • Centre for Human Drug Research

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

A

B

C

D

AA

BB

CC

DD

Arm Description

50 mg ISIS 325568 vs Placebo, s.c. injection

100 mg ISIS 325568 vs Placebo , s.c. injection

200 mg ISIS 325568 vs Placebo , s.c. injection

400 mg ISIS 325568 vs Placebo, s.c. injection

50 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo

100 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo

200 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo

400 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo

Outcomes

Primary Outcome Measures

safety and tolerability

Secondary Outcome Measures

Pharmacokinetic profile all doses and Pharmacodynamics for multi-dose groups.

Full Information

First Posted
August 21, 2007
Last Updated
August 15, 2008
Sponsor
Ionis Pharmaceuticals, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00519727
Brief Title
Safety Study of ISIS 325568 in Healthy Volunteers
Official Title
A Phase I, Double-Blind, Placebo-Controlled, Dose- Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 325568 Administered to Healthy Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
August 2008
Overall Recruitment Status
Completed
Study Start Date
August 2007 (undefined)
Primary Completion Date
April 2008 (Actual)
Study Completion Date
June 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Ionis Pharmaceuticals, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary purpose of this trial is to assess the safety of ISIS 325568 when given at increasing single doses and to assess the safety of the same doses when given multiple times.
Detailed Description
To evaluate the safety of a single subcutaneous injection of ISIS 325568 administered at four increasing dose levels (50, 100, 200, 400 mg/week) and to evaluate the safety and tolerability of multiple doses of ISIS 325568 (three intravenous doses during Study Week 1, followed by once weekly subcutaneous administration for 5 weeks) at each of the four dose levels

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Experimental
Arm Description
50 mg ISIS 325568 vs Placebo, s.c. injection
Arm Title
B
Arm Type
Experimental
Arm Description
100 mg ISIS 325568 vs Placebo , s.c. injection
Arm Title
C
Arm Type
Experimental
Arm Description
200 mg ISIS 325568 vs Placebo , s.c. injection
Arm Title
D
Arm Type
Experimental
Arm Description
400 mg ISIS 325568 vs Placebo, s.c. injection
Arm Title
AA
Arm Type
Experimental
Arm Description
50 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
Arm Title
BB
Arm Type
Experimental
Arm Description
100 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
Arm Title
CC
Arm Type
Experimental
Arm Description
200 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
Arm Title
DD
Arm Type
Experimental
Arm Description
400 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
Intervention Type
Drug
Intervention Name(s)
ISIS 325568
Intervention Description
4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg Placebo: 0.9% Sodium Chloride
Primary Outcome Measure Information:
Title
safety and tolerability
Time Frame
30 days for single dose, 16 weeks for multi-dose
Secondary Outcome Measure Information:
Title
Pharmacokinetic profile all doses and Pharmacodynamics for multi-dose groups.
Time Frame
4 days for single dose, 16 weeks for multi-dose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age 18 to 65 years Males or females. Females must be non-pregnant and non-lactating, and either surgically sterile (hysterectomy, oophorectomy, or tubal ligation) or post-menopausal. Males must be surgically sterile, abstinent or if engaged in sexual relations of child-bearing potential, subject or partner must be using an acceptable contraceptive method during the trial and for 9 weeks after the last dose of study drug. Give written informed consent to participate in study and availability for all study requirements Fasting plasma glucose ≤ the upper limit of the laboratory's reference range (ULN) HbA1C ≤ ULN BMI < 30 kg/m2 Exclusion Criteria: Clinically significant abnormalities in medical history or physical examination Abnormalities on laboratory examination (ALT > ULN, AST > ULN, bilirubin > ULN, creatinine > ULN, urine protein positive by urine dipstick, platelets < lower limit of normal and any other clinically significant laboratory findings) History of clinically significant abnormalities in coagulation parameters Positive test result for HIV, hepatitis B virus, and/or hepatitis C virus Active infection requiring antiviral or antimicrobial therapy Subjects on chronic or acute prescription medication may be permitted after discussion with the Isis Medical Monitor. Malignancy (with the exception of basal or squamous cell carcinoma of the skin if adequately treated and no recurrence for > 1 year) Any other concurrent condition which, in the opinion of the Investigator, would preclude participation in this study or interfere with compliance History of alcohol or drug abuse Undergoing or have undergone treatment with another investigational drug, biologic agent or device within 90 days prior to Screening. Blood donation within three months of screening
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
J. Burggraaf, MD PhD
Organizational Affiliation
Centre for Human Drug Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre for Human Drug Research
City
Leiden
Country
Netherlands

12. IPD Sharing Statement

Citations:
PubMed Identifier
35976085
Citation
Burel SA, Machemer T, Baker BF, Kwoh TJ, Paz S, Younis H, Henry SP. Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear Cells. Nucleic Acid Ther. 2022 Dec;32(6):457-472. doi: 10.1089/nat.2022.0033. Epub 2022 Aug 17.
Results Reference
derived

Learn more about this trial

Safety Study of ISIS 325568 in Healthy Volunteers

We'll reach out to this number within 24 hrs